Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments
March 10, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug to Participate in Three Upcoming Medical and Investor Conferences
February 03, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline
January 20, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments
November 11, 2021 16:04 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
November 01, 2021 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference
September 30, 2021 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
September 28, 2021 07:30 ET
|
Graybug Vision, Inc.
55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden for patients...
Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference
September 21, 2021 17:15 ET
|
Graybug Vision, Inc.
BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments
August 11, 2021 16:05 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...